EP3169336A4 - Zusammensetzungen zum targeting von makrophagen und anderen cd206-hochexprimierenden zellen sowie verfahren zur behandlung und diagnose - Google Patents
Zusammensetzungen zum targeting von makrophagen und anderen cd206-hochexprimierenden zellen sowie verfahren zur behandlung und diagnose Download PDFInfo
- Publication number
- EP3169336A4 EP3169336A4 EP15822654.8A EP15822654A EP3169336A4 EP 3169336 A4 EP3169336 A4 EP 3169336A4 EP 15822654 A EP15822654 A EP 15822654A EP 3169336 A4 EP3169336 A4 EP 3169336A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- diagnosis
- compositions
- treating
- methods
- expressing cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 210000002540 macrophage Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025991P | 2014-07-17 | 2014-07-17 | |
| US201462027220P | 2014-07-21 | 2014-07-21 | |
| US201462027193P | 2014-07-21 | 2014-07-21 | |
| US201462027733P | 2014-07-22 | 2014-07-22 | |
| PCT/US2015/041019 WO2016011419A1 (en) | 2014-07-17 | 2015-07-17 | Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3169336A1 EP3169336A1 (de) | 2017-05-24 |
| EP3169336A4 true EP3169336A4 (de) | 2018-04-04 |
Family
ID=55079110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP15822654.8A Pending EP3169336A4 (de) | 2014-07-17 | 2015-07-17 | Zusammensetzungen zum targeting von makrophagen und anderen cd206-hochexprimierenden zellen sowie verfahren zur behandlung und diagnose |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3169336A4 (de) |
| CA (1) | CA2955441C (de) |
| WO (1) | WO2016011419A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100196272A1 (en) | 2009-01-30 | 2010-08-05 | Neoprobe Corporation | Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
| JP6722663B2 (ja) * | 2014-07-17 | 2020-07-15 | オハイオ ステート イノベーション ファウンデーション | マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法 |
| US10806803B2 (en) | 2014-07-17 | 2020-10-20 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis |
| US20180092998A1 (en) * | 2016-10-04 | 2018-04-05 | Cardinal Health, 414 Llc | Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier |
| MX2019004029A (es) | 2016-10-07 | 2019-09-27 | Navidea Biopharmaceuticals Inc | Compuestos y metodos para diagnosis y tratamiento de infecciones virales. |
| CA3039424A1 (en) | 2016-10-07 | 2018-04-12 | Navidea Biopharmaceuticals, Inc. | Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same |
| CA3070494A1 (en) * | 2017-07-21 | 2019-01-24 | Navidea Biopharmaceuticals, Inc. | Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions |
| CN112840211A (zh) * | 2018-08-27 | 2021-05-25 | 南特生物公司 | Rp182组合物及方法 |
| WO2020198622A1 (en) * | 2019-03-27 | 2020-10-01 | Navidea Biopharmaceuticals, Inc. | Compositions and methods for altering macrophage phenotype |
| CA3155675A1 (en) * | 2019-09-30 | 2021-04-08 | Navidea Biopharmaceuticals, Inc. | Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands |
| EP4076540A4 (de) | 2020-07-08 | 2024-02-21 | Navidea Biopharmaceuticals Inc | Synthese von mannosylierten dextranen mit einheitlich definiertem molekulargewicht und deren derivaten |
| US11833170B2 (en) | 2022-02-04 | 2023-12-05 | Navidea Biopharmaceuticals, Inc. | Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking |
| US12006339B2 (en) | 2022-05-20 | 2024-06-11 | Navidea Biopharmaceuticals, Inc. | CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1069820A (en) * | 1965-12-21 | 1967-05-24 | Akad Wissenschaften Ddr | Tuberculostatic compounds |
| US6409990B1 (en) * | 1999-05-14 | 2002-06-25 | The Regents Of The University Of California | Macromolecular carrier for drug and diagnostic agent delivery |
| WO2012169973A1 (en) * | 2011-06-09 | 2012-12-13 | Agency For Science, Technology And Research | A core-shell nanoparticle |
| WO2016011415A2 (en) * | 2014-07-17 | 2016-01-21 | Ohio State Innovation Foundation | Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same |
-
2015
- 2015-07-17 CA CA2955441A patent/CA2955441C/en active Active
- 2015-07-17 EP EP15822654.8A patent/EP3169336A4/de active Pending
- 2015-07-17 WO PCT/US2015/041019 patent/WO2016011419A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1069820A (en) * | 1965-12-21 | 1967-05-24 | Akad Wissenschaften Ddr | Tuberculostatic compounds |
| US6409990B1 (en) * | 1999-05-14 | 2002-06-25 | The Regents Of The University Of California | Macromolecular carrier for drug and diagnostic agent delivery |
| WO2012169973A1 (en) * | 2011-06-09 | 2012-12-13 | Agency For Science, Technology And Research | A core-shell nanoparticle |
| WO2016011415A2 (en) * | 2014-07-17 | 2016-01-21 | Ohio State Innovation Foundation | Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same |
Non-Patent Citations (3)
| Title |
|---|
| COESSENS V ET AL: "Synthesis of polyglutamine and dextran conjugates of streptomycin with an acid-sensitive drug-carrier linkage", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 38, no. 2, 1 February 1996 (1996-02-01), pages 141 - 150, XP004037399, ISSN: 0168-3659, DOI: 10.1016/0168-3659(95)00111-5 * |
| DOU HONGJING ET AL: "Facile preparation and drug delivery behavior of novel dextran-based nanogels conjugated with doxorubicin via a pH-labile bond", JOURNAL OF CONTROLLED RELEASE, vol. 172, no. 1, 2013, XP028773131, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2013.08.139 * |
| See also references of WO2016011419A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2955441C (en) | 2023-03-14 |
| EP3169336A1 (de) | 2017-05-24 |
| WO2016011419A1 (en) | 2016-01-21 |
| CA2955441A1 (en) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3169336A4 (de) | Zusammensetzungen zum targeting von makrophagen und anderen cd206-hochexprimierenden zellen sowie verfahren zur behandlung und diagnose | |
| EP3377042A4 (de) | Materialien und verfahren zur behandlung von titinbasierten myopathien und anderen titinopathien | |
| EP3313404A4 (de) | Therapeutische zusammensetzungen, kombinationen und verfahren zur verwendung | |
| EP3328399A4 (de) | Modifizierte zellen und therapieverfahren | |
| EP3368559A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
| EP3288958A4 (de) | Zusammensetzungen aus obeticholsäure und verfahren zur verwendung | |
| EP3230460A4 (de) | Verfahren und zusammensetzungen zur selektiven eliminierung von bestimmten zellen | |
| EP3218390A4 (de) | Gezielte xten-konjugatzusammensetzungen und verfahren zur herstellung davon | |
| EP3218492A4 (de) | Unterbrechung und feldaktivierte bereitstellung von verbindungen und zusammensetzungen an zellen | |
| EP3094720A4 (de) | Zusammensetzungen und verfahren zur herstellung von atemwegszellen | |
| EP3167046A4 (de) | Herstellung und kryokonservierung von fucosylierten zellen zur therapeutischen verwendung | |
| EP3134130A4 (de) | Zusammensetzungen und verfahren zur behandlung von hämoglobinopathien | |
| EP3207048A4 (de) | Zusammensetzungen und verfahren zur behandlung von muskeldystrophie | |
| EP3139935A4 (de) | Therapeutische plazentale zusammensetzungen, verfahren zur herstellung und verfahren zur verwendung | |
| EP3186286A4 (de) | Cellulosehaltige zusammensetzungen und verfahren zur herstellung davon | |
| EP3341391A4 (de) | Zusammensetzungen und verfahren zur schmerzbehandlung | |
| EP3256110A4 (de) | Zusammensetzungen und verfahren zur tumorbehandlung mit nanopartikeln | |
| EP3169792A4 (de) | Verbindungen und zusammensetzungen zum targeting von makrophagen und anderen mannose-bindenden c-typ-lektinrezeptor-hochexprimierenden zellen und verfahren zur behandlung und diagnose damit | |
| EP3021839A4 (de) | Verfahren und zusammensetzungen zur behandlung von fibrose | |
| EP3139928A4 (de) | Anordrin-zusammensetzungen und verfahren zur behandlung von krankheiten | |
| EP3353204A4 (de) | Verfahren und zusammensetzungen für die behandlung von krebs | |
| EP3151786A4 (de) | Zusammensetzungen und verfahren zur regeneration von harten geweben | |
| EP3105327A4 (de) | Zusammensetzungen und verfahren zur verwendung von mikrorna-inhibitoren | |
| EP3352771A4 (de) | Nabelschnurgewebezusammensetzungen und verfahren zur verwendung | |
| EP3125963A4 (de) | Gewebefüllerzusammensetzungen und verfahren zur verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20170209 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CARDINAL HEALTH 414, LLC Owner name: OHIO STATE INNOVATION FOUNDATION Owner name: COPE, FRED Owner name: SCHLESINGER, LARRY Owner name: BACHELDER, ERIC |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20180301 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/721 20060101ALN20180223BHEP Ipc: A61P 35/00 20060101ALI20180223BHEP Ipc: A61K 47/54 20170101ALI20180223BHEP Ipc: A61P 31/06 20060101ALI20180223BHEP Ipc: A61K 49/00 20060101ALI20180223BHEP Ipc: A61K 47/61 20170101AFI20180223BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20200122 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |